Correction: Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) (Genetics in Medicine, (2018), 20, 9, (899-909), 10.1038/s41436-018-0039-z)

on behalf of the ACMG Professional Practice and Guidelines Committee

Research output: Contribution to journalComment/debate

Abstract

In the original version of this Article, the Statement on Conflict of Interest originally submitted by the authors was not published and should have read: Disclosure: R.E.H. has served as a consultant for Array Biopharma. C.Y.H. has served as a consultant and has received research support from MyoKardia. D.P.J. has served as a consultant for Array Biopharma, Eidos Therapeutics, Glaxo Smith Kline, Invitae, MyoKardia, and Pfizer. M.R.G.T. has served as a consultant for Array Biopharma, Guidepoint Global, and Wellpoint, Inc., and has served as a speaker for GeneDx. M.V. is employed by Invitae Corporation. The other authors declare no conflicts of interest. Furthermore, in the Acknowledgements section we neglected to state that: This article is an abbreviated version of “Genetic Evaluation of Cardiomyopathy—a Heart Failure Society of America Practice Guideline,” published in Journal of Cardiac Failure, and on which the American College of Medical Genetics and Genomics and the Heart Failure Society of America collaborated. The PDF and HTML versions of the Article have now been corrected with the above.

Original languageEnglish (US)
JournalGenetics in Medicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Consultants
Genomics
Cardiomyopathies
Medicine
Conflict of Interest
Disclosure
Practice Guidelines
Heart Failure
Therapeutics

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

@article{76b74a4d0dba4895930b9231ef7ad44b,
title = "Correction: Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) (Genetics in Medicine, (2018), 20, 9, (899-909), 10.1038/s41436-018-0039-z)",
abstract = "In the original version of this Article, the Statement on Conflict of Interest originally submitted by the authors was not published and should have read: Disclosure: R.E.H. has served as a consultant for Array Biopharma. C.Y.H. has served as a consultant and has received research support from MyoKardia. D.P.J. has served as a consultant for Array Biopharma, Eidos Therapeutics, Glaxo Smith Kline, Invitae, MyoKardia, and Pfizer. M.R.G.T. has served as a consultant for Array Biopharma, Guidepoint Global, and Wellpoint, Inc., and has served as a speaker for GeneDx. M.V. is employed by Invitae Corporation. The other authors declare no conflicts of interest. Furthermore, in the Acknowledgements section we neglected to state that: This article is an abbreviated version of “Genetic Evaluation of Cardiomyopathy—a Heart Failure Society of America Practice Guideline,” published in Journal of Cardiac Failure, and on which the American College of Medical Genetics and Genomics and the Heart Failure Society of America collaborated. The PDF and HTML versions of the Article have now been corrected with the above.",
author = "{on behalf of the ACMG Professional Practice and Guidelines Committee} and Hershberger, {Ray E.} and Givertz, {Michael M.} and Ho, {Carolyn Y.} and Judge, {Daniel P.} and Kantor, {Paul F.} and McBride, {Kim L.} and Ana Morales and Taylor, {Matthew R.G.} and Matteo Vatta and Stephanie Ware",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41436-019-0521-2",
language = "English (US)",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Correction

T2 - Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) (Genetics in Medicine, (2018), 20, 9, (899-909), 10.1038/s41436-018-0039-z)

AU - on behalf of the ACMG Professional Practice and Guidelines Committee

AU - Hershberger, Ray E.

AU - Givertz, Michael M.

AU - Ho, Carolyn Y.

AU - Judge, Daniel P.

AU - Kantor, Paul F.

AU - McBride, Kim L.

AU - Morales, Ana

AU - Taylor, Matthew R.G.

AU - Vatta, Matteo

AU - Ware, Stephanie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the original version of this Article, the Statement on Conflict of Interest originally submitted by the authors was not published and should have read: Disclosure: R.E.H. has served as a consultant for Array Biopharma. C.Y.H. has served as a consultant and has received research support from MyoKardia. D.P.J. has served as a consultant for Array Biopharma, Eidos Therapeutics, Glaxo Smith Kline, Invitae, MyoKardia, and Pfizer. M.R.G.T. has served as a consultant for Array Biopharma, Guidepoint Global, and Wellpoint, Inc., and has served as a speaker for GeneDx. M.V. is employed by Invitae Corporation. The other authors declare no conflicts of interest. Furthermore, in the Acknowledgements section we neglected to state that: This article is an abbreviated version of “Genetic Evaluation of Cardiomyopathy—a Heart Failure Society of America Practice Guideline,” published in Journal of Cardiac Failure, and on which the American College of Medical Genetics and Genomics and the Heart Failure Society of America collaborated. The PDF and HTML versions of the Article have now been corrected with the above.

AB - In the original version of this Article, the Statement on Conflict of Interest originally submitted by the authors was not published and should have read: Disclosure: R.E.H. has served as a consultant for Array Biopharma. C.Y.H. has served as a consultant and has received research support from MyoKardia. D.P.J. has served as a consultant for Array Biopharma, Eidos Therapeutics, Glaxo Smith Kline, Invitae, MyoKardia, and Pfizer. M.R.G.T. has served as a consultant for Array Biopharma, Guidepoint Global, and Wellpoint, Inc., and has served as a speaker for GeneDx. M.V. is employed by Invitae Corporation. The other authors declare no conflicts of interest. Furthermore, in the Acknowledgements section we neglected to state that: This article is an abbreviated version of “Genetic Evaluation of Cardiomyopathy—a Heart Failure Society of America Practice Guideline,” published in Journal of Cardiac Failure, and on which the American College of Medical Genetics and Genomics and the Heart Failure Society of America collaborated. The PDF and HTML versions of the Article have now been corrected with the above.

UR - http://www.scopus.com/inward/record.url?scp=85065205795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065205795&partnerID=8YFLogxK

U2 - 10.1038/s41436-019-0521-2

DO - 10.1038/s41436-019-0521-2

M3 - Comment/debate

AN - SCOPUS:85065205795

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

ER -